Skip to main content

Signal Intensity Ratio of Cochlear Basal Turn Increased in Affected Ear in Meniere Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 2, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 2, 2024 -- The affected ear in Meniere disease has significantly increased the signal intensity ratio (SIR) of the cochlear basal turn, indicating potential damage of the blood-labyrinth barrier, according to a study published online Dec. 6 in the European Archives of Oto-Rhino-Laryngology.

Weidong Zhang, M.D., from the Zhengzhou University People's Hospital and Henan Provincial People's Hospital in China, and colleagues enrolled 30 patients with unilateral definite Meniere disease and 24 healthy controls to compare the SIR of the cochlear basal turn. The differences of bilateral SIR were compared between Meniere disease and healthy controls, and the correlation was examined between the SIR of the affected ear and the grades of cochlear and vestibular hydrops in Meniere disease.

The researchers observed a significant increase in the SIR of the affected ear in Meniere disease versus the unaffected ear. Healthy controls had no significant difference in SIR between the two ears. The SIR was higher in the unaffected ear in Meniere disease than that of both ears in healthy controls. There was a positive correlation observed for SIR in the affected ear in Meniere disease with hydrops in both the cochlea and vestibula.

"As increased permeability of the blood-labyrinth barrier precedes the formation of endolymphatic hydrops, it is suggested that disruption of the blood-labyrinth barrier may contribute to the development of Meniere disease in patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.